News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
627,562 Results
Type
Article (46033)
Company Profile (193)
Press Release (581336)
Section
Business (179308)
Career Advice (2587)
Deals (32489)
Drug Delivery (119)
Drug Development (80062)
Employer Resources (151)
FDA (15209)
Job Trends (14055)
News (315043)
Policy (31538)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (13)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Standard (1)
Academia (2649)
Academic (1)
Accelerated approval (2)
Adcomms (29)
Allergies (71)
Alliances (45667)
ALS (81)
Alzheimer's disease (1370)
Antibody-drug conjugate (ADC) (122)
Approvals (15178)
Artificial intelligence (224)
Autoimmune disease (13)
Automation (14)
Bankruptcy (334)
Best Places to Work (10893)
BIOSECURE Act (17)
Biosimilars (102)
Biotechnology (106)
Bladder cancer (53)
Brain cancer (24)
Breast cancer (227)
Cancer (1784)
Cardiovascular disease (147)
Career advice (2161)
Career pathing (32)
CAR-T (136)
Cell therapy (371)
Cervical cancer (11)
Clinical research (64657)
Collaboration (677)
Compensation (276)
Complete response letters (27)
COVID-19 (2597)
CRISPR (35)
C-suite (186)
Cystic fibrosis (92)
Data (1672)
Decentralized trials (2)
Denatured (21)
Depression (44)
Diabetes (229)
Diagnostics (5907)
Digital health (13)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (107)
Drug pricing (114)
Drug shortages (30)
Duchenne muscular dystrophy (60)
Earnings (66239)
Editorial (32)
Employer branding (19)
Employer resources (135)
Events (91877)
Executive appointments (611)
FDA (16127)
Featured Employer (38)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (598)
Gene editing (86)
Generative AI (22)
Gene therapy (273)
GLP-1 (734)
Government (4437)
Grass and pollen (3)
Guidances (43)
Healthcare (17134)
Huntington's disease (24)
IgA nephropathy (23)
Immunology and inflammation (97)
Indications (21)
Infectious disease (2724)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (43)
Intellectual property (66)
Interviews (531)
IPO (14393)
IRA (46)
Job creations (3588)
Job search strategy (1786)
Kidney cancer (10)
Labor market (21)
Layoffs (463)
Leadership (19)
Legal (7294)
Liver cancer (69)
Lung cancer (272)
Lymphoma (120)
Machine learning (2)
Management (54)
Manufacturing (250)
MASH (62)
Medical device (11151)
Medtech (11156)
Mergers & acquisitions (18455)
Metabolic disorders (627)
Multiple sclerosis (63)
NASH (23)
Neurodegenerative disease (84)
Neuropsychiatric disorders (28)
Neuroscience (1837)
NextGen: Class of 2025 (6129)
Non-profit (4209)
Northern California (1937)
Now hiring (31)
Obesity (349)
Opinion (247)
Ovarian cancer (63)
Pain (76)
Pancreatic cancer (68)
Parkinson's disease (122)
Partnered (16)
Patents (180)
Patient recruitment (79)
Peanut (41)
People (56160)
Pharmaceutical (81)
Pharmacy benefit managers (21)
Phase I (19966)
Phase II (28390)
Phase III (21532)
Pipeline (803)
Podcasts (81)
Policy (113)
Postmarket research (2582)
Preclinical (8208)
Press Release (62)
Prostate cancer (83)
Psychedelics (37)
Radiopharmaceuticals (234)
Rare diseases (342)
Real estate (5372)
Recruiting (60)
Regulatory (21651)
Reports (28)
Research institute (2311)
Resumes & cover letters (386)
Rett syndrome (2)
RNA editing (1)
RSV (40)
Schizophrenia (68)
Series A (107)
Series B (68)
Service/supplier (10)
Sickle cell disease (51)
Southern California (1689)
Special edition (16)
Sponsored (27)
Startups (3279)
State (2)
Stomach cancer (13)
Supply chain (59)
The Weekly (59)
United States (17383)
Vaccines (631)
Venture capitalists (32)
Webinars (12)
Weight loss (259)
Women's health (26)
Worklife (16)
Date
Today (166)
Last 7 days (759)
Last 30 days (2699)
Last 365 days (32409)
2025 (5223)
2024 (33167)
2023 (37223)
2022 (48028)
2021 (51854)
2020 (50643)
2019 (43939)
2018 (33317)
2017 (30844)
2016 (29877)
2015 (34709)
2014 (27674)
2013 (23114)
2012 (24600)
2011 (25397)
2010 (22957)
Location
Africa (833)
Alabama (47)
Alaska (5)
Arizona (143)
Arkansas (12)
Asia (39797)
Australia (7323)
California (4415)
Canada (1680)
China (404)
Colorado (218)
Connecticut (197)
Delaware (109)
Europe (86280)
Florida (693)
Georgia (145)
Idaho (49)
Illinois (439)
India (20)
Indiana (258)
Iowa (4)
Japan (127)
Kansas (88)
Kentucky (24)
Louisiana (7)
Maine (48)
Maryland (728)
Massachusetts (3345)
Michigan (185)
Minnesota (302)
Mississippi (2)
Missouri (66)
Montana (23)
Nebraska (23)
Nevada (49)
New Hampshire (63)
New Jersey (1336)
New Mexico (26)
New York (1308)
North Carolina (803)
North Dakota (5)
Northern California (1937)
Ohio (158)
Oklahoma (7)
Oregon (34)
Pennsylvania (1022)
Puerto Rico (7)
Rhode Island (21)
South America (1158)
South Carolina (13)
South Dakota (1)
Southern California (1689)
Tennessee (76)
Texas (659)
Utah (150)
Virginia (118)
Washington D.C. (52)
Washington State (437)
West Virginia (3)
Wisconsin (39)
627,562 Results for "gc pharma formerly known as green cross".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
FDA Grants Fast Track Designation to GCBP and Novel Pharma’s GC1130A
GC Biopharma and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA treatment, GC1130A.
June 10, 2024
·
4 min read
Policy
GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma and Novel Pharma announced that its jointly developed MPS IIIA ‘GC1130A’ treatment has received FDA IND approval.
May 20, 2024
·
2 min read
Policy
GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
GC Biopharma and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug application for their jointly developed MPSIIIA treatment, GC1130A.
May 21, 2024
·
2 min read
Press Releases
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment
November 26, 2024
·
3 min read
Press Releases
GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025
February 11, 2025
·
3 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
Policy
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma’s Treatment for Sanfilippo Syndrome (Type A)
GC Biopharma Corp. announced that the European Medicines Agency has granted Orphan Drug Designation to its intracerebroventricular Enzyme Replacement Therapy candidate, GC1130A, designed for Sanfilippo Syndrome type A, developed in collaboration with Novel Pharma.
January 22, 2024
·
2 min read
Press Releases
GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
October 28, 2024
·
3 min read
1 of 62,757
Next
